The present study focused on the impact of CYP1A2 and CYP2D6 genetic polymorphisms as well as CYP1A2 metabolizing capacity influenced by non-genetic factors (sex, age, smoking behaviour) on olanzapine blood concentration in patients with psychiatric disorders. This evidence concerns the gene CYP1A2 and psychiatric disorder.